State Street Corp Purchases 32,641 Shares of Novo Nordisk A/S $NVO

Key Points

• State Street increased its Novo Nordisk position by 0.6%, purchasing 32,641 additional shares to own 5.87 million shares valued at approximately $284.6 million. Institutional investors collectively hold 11.54% of the company.
• Analyst sentiment remains cautious: Novo Nordisk has an average “Hold” rating from MarketBeat-tracked analysts, with an average price target of $64.94.
• Novo’s pipeline offers potential upside, particularly from the CagriSema obesity drug, but intense competition from Eli Lilly and concerns over slowing GLP-1 growth continue to weigh on investor sentiment.

State Street Corp boosted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 0.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,869,834 shares of the company's stock after purchasing an additional 32,641 shares during the period. State Street Corp owned about 0.13% of Novo Nordisk A/S worth $284,565,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in NVO. CoreCap Advisors LLC boosted its position in shares of Novo Nordisk A/S by 4.7% in the second quarter. CoreCap Advisors LLC now owns 5,341 shares of the company's stock worth $256,000 after acquiring an additional 242 shares during the last quarter. Carson Advisory Inc. increased its position in Novo Nordisk A/S by 2.2% during the first quarter. Carson Advisory Inc. now owns 12,316 shares of the company's stock worth $453,000 after purchasing an additional 268 shares during the last quarter. Bradley Foster & Sargent Inc. CT raised its stake in Novo Nordisk A/S by 0.6% during the first quarter. Bradley Foster & Sargent Inc. CT now owns 46,960 shares of the company's stock worth $1,726,000 after purchasing an additional 272 shares during the period. Arlington Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 4.4% in the 2nd quarter. Arlington Partners LLC now owns 6,777 shares of the company's stock valued at $325,000 after purchasing an additional 283 shares during the last quarter. Finally, Parkside Financial Bank & Trust grew its stake in shares of Novo Nordisk A/S by 13.1% during the 2nd quarter. Parkside Financial Bank & Trust now owns 2,436 shares of the company's stock valued at $117,000 after buying an additional 283 shares during the period. Institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

NVO has been the topic of several research analyst reports. Citigroup reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Weiss Ratings raised shares of Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th. BMO Capital Markets reaffirmed a "market perform" rating and set a $47.00 price target on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Berenberg Bank set a $47.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, August 12th. Finally, Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 20th. Three investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $64.94.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema delivered encouraging late-stage data. Novo said its investigational once-weekly drug produced greater weight loss than Eli Lilly’s tirzepatide in the REIMAGINE 5 trial, including approximately 21% weight loss in obesity. The results support CagriSema as a potential future competitor to Lilly’s Zepbound. CagriSema trial results
• Positive Sentiment: Pipeline diversification is advancing. Frehemgo and Sogroya received positive opinions from European regulators, while Singapore approved Wegovy for certain liver-related conditions. Novo also plans to pursue additional blockbuster drugs, including opportunities in hair loss and rare diseases. Rare disease pipeline
• Neutral Sentiment: Novo is open to a direct NYSE listing. CEO Mike Doustdar said a direct New York listing could improve the company’s U.S. profile, where more than half of revenue is generated. However, Novo is not currently pursuing a change from its existing American depositary receipt structure, so the near-term financial impact is limited. New York listing report
• Neutral Sentiment: Management is considering acquisitions and expanded AI use. Potential M&A could strengthen gaps in Novo’s obesity and broader drug pipeline, while its Anthropic partnership aims to improve drug discovery. These initiatives offer longer-term potential but add execution and spending uncertainty.
• Negative Sentiment: Investors were underwhelmed by the company’s long-term strategy. Novo’s capital-markets presentation and $23 billion risk-adjusted pipeline target did not sufficiently reassure investors that growth can withstand slowing GLP-1 momentum and semaglutide’s approaching patent cliff. Capital markets day coverage
• Negative Sentiment: Competitive pressure remains intense. Eli Lilly leads Novo in GLP-1 market share and investor sentiment, while Viking Therapeutics’ positive maintenance data highlighted the threat from emerging drugs with less frequent dosing. Jefferies maintained a Hold rating, reinforcing cautious sentiment. Competition analysis

Novo Nordisk A/S Stock Down 3.1%

NYSE:NVO opened at $38.19 on Thursday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. The stock has a 50 day moving average of $46.21 and a 200-day moving average of $43.87. The firm has a market capitalization of $170.51 billion, a PE ratio of 9.34, a price-to-earnings-growth ratio of 1.30 and a beta of 0.74. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. The business had revenue of $11.98 billion for the quarter. Analysts predict that Novo Nordisk A/S will post 3.52 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were paid a $0.5786 dividend. The ex-dividend date of this dividend was Monday, August 17th. This represents a dividend yield of 258.0%. Novo Nordisk A/S's dividend payout ratio is presently 19.80%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.